Genetic testing, powered for prostate cancer

Improve outcomes with genetic testing


Why consider genetic testing for prostate cancer?

According to a recent NEJM study:

  • >11%  of men with metastatic prostate cancer have an inherited mutation
  • Patients with metastatic prostate cancer are 4X more likely to have a BRCA1 and BRCA2 mutation
  • 40.3%  of men with BRCA2 mutations are more likely to develop advanced prostate cancer
  • Family history alone cannot reliably predict an inherited DNA-repair defect that may have risk of disease associated with metastatic prostate cancer

Invitae Prostate Cancer Panel

Invitae offers comprehensive genetic testing for patients at risk for hereditary prostate cancer. More than 180,000 cases of prostate cancer are diagnosed each year; 5-10% of those are expected to be hereditary.1,2

Pathogenic variants in BRCA1 and BRCA2 are only part of the story. Invitae’s comprehensive prostate cancer panel targets up to 14 genes that evidence associates with a hereditary predisposition to prostate cancer:

ATM,  BRCA1,  BRCA2,  CHEK2,  EPCAM,  HOXB13,  MLH1,  MSH2,  MSH6,  NBN,  PALB2,  PMS2,  RAD51D,  TP53

Results from the Invitae Prostate Cancer Panel can help guide medical management for both your patient and their family, including treatments such as PARP inhibitors and screening protocols.


Who should be considered for genetic testing?

This panel may be appropriate if your patient or their family members have:

  • High-grade prostate cancer (metastatic or Gleason score ≥7)
  • Rare cancers including male breast cancer or ovarian cancer
  • Cancer diagnosed at a young age (<50 years)
  • Multiple cancers (e.g., 2+ primary cancers in the same person or 3+ ­­­diagnoses on the same side of the family)
  • A known pathogenic genetic variant in the family

Lifetime cancer risks for prostate cancer genes

Simple pricing. Simple billing. No surprises.

  • Panel testing that lets you take cost out of the equation, with no explanation of benefits >$1500 ever
  • Clinical Consult Services to help identify the right test for each patient and clarify results, at no additional charge

Fast, customizable testing

Quick turnaround

Results available in 10–21 calendar days (14 days on average).

Clinical support

Expert advice and counseling for you and your patient when you need it.

Learn more

Need more answers?

Order additional genes within the original clinical area at no additional charge within 90 days.

Learn more

1Cancer Genome Atlas Research Network. Cell, 2015.

2Pritchard, CC. et al. NEJM, 2016.

3Piper LW Nicolosi, et al. Presented at ASCO Annual Meeting; June 2017; Chicago, Illinois.